Market Place
Sourcing Support
Pfizer reports positive results from Echelon-3 study
17 Jun 2024 //
INDIANPHARMAPOST
Takeda and Pfizer announce results from Positive Phase 3
03 Jun 2024 //
PRESS RELEASE
ADCETRIS Regimen Improves OS In Relapsed/Refractory DLBCL
01 Jun 2024 //
BUSINESSWIRE
Frontline ADCETRIS Combo Shows 4-Year Survival Benefit In Hodgkin Lymphoma
01 Jun 2024 //
BUSINESSWIRE
Seagen’s former commercial chief joins the board at healthcare agency
22 Mar 2024 //
ENDPTS
Pfizer`s blood cancer therapy Adcetris succeeds in late-stage trial
13 Mar 2024 //
PRESS RELEASE
Seagen Highlights First Solid Tumor Data for an ADCETRIS
03 Nov 2023 //
BUSINESSWIRE
Data for ADCETRIS with Combination in Hodgkin Lymphoma to be Featured
02 Nov 2023 //
BUSINESSWIRE
EC Approves ADCETRI for Previously Untreated CD30+ Stage III Hodgkin Lymphoma
18 Oct 2023 //
BUSINESSWIRE
Brentuximab Vedotin Plus AVD Gets Positive CHMP Opinion
18 Sep 2023 //
ONCLIVE
BrECADD Proves Noninferior to eBEACOPP in Advanced Classical Hodgkin Lymphoma
22 Jun 2023 //
ONCLIVE
Ph3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows
20 Jun 2023 //
BUSINESSWIRE
MindMed Provides Overview of Clinical Progress & Corporate Updates
20 Jun 2023 //
BUSINESSWIRE
FDA advisers back XBB-targeted COVID shots for 2023-24 campaign
15 Jun 2023 //
REUTERS
6-Year Overall Survival Results Added to Prescribing Information for ADCETRIS
14 Jun 2023 //
BUSINESSWIRE
Seagen touts PhII data for Adcetris combo; A-Alpha partners with Gilead on HIV
13 Jun 2023 //
ENDPTS
Seagen Announces ADCETRIS Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate
13 Jun 2023 //
BUSINESSWIRE
Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris
13 Dec 2022 //
BIOSPACE
Seagen to Highlight ADCETRIS Clinical Progress at the 2022 ASH
01 Dec 2022 //
BUSINESSWIRE
Seagen Caps Busy Week with FDA Nod in Pediatric Hodgkin Lymphoma
12 Nov 2022 //
BIOSPACE
Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS
11 Nov 2022 //
PRESS RELEASE
ADCETRIS Plus SoC Chemotherapy Demonstrates Superior EFS vs. SoC Alone
03 Jun 2022 //
BUSINESSWIRE
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
09 Feb 2022 //
BUSINESSWIRE
Seagen Announces Preliminary Results from Phase 2 Trial of ADCETRIS
12 Dec 2021 //
BUSINESSWIRE
Seagen Reports Third Quarter 2021 Financial Results
28 Oct 2021 //
BUSINESSWIRE
The top 10 antibody drug conjugate contenders in 2021
13 Sep 2021 //
FIERCEPHARMA
Seagen Announces Multiple ADCETRIS® (Brentuximab Vedotin)
05 Nov 2020 //
BUSINESSWIRE
Seagen Reports Third Quarter 2020 Financial Results
30 Oct 2020 //
BUSINESSWIRE
Merck`s Seattle Genetics ADC deal extends blockbuster Keytruda franchise
16 Sep 2020 //
FIERCE PHARMA
NICE backing for Takeda`s Adcetris for rare lymphoma
10 Jul 2020 //
PHARMATIMES
NICE recommends ADCETRIS? (brentuximab vedotin), in combination chemotherapy
09 Jul 2020 //
PHARMAFIELD
Genmab, Seattle Genetics eye FDA filing for new cancer med after latest
30 Jun 2020 //
FIERCE PHARMA
EHA25Virtual: A New Paradigm in Relapsed Refractory Hodgkin Lymphoma
12 Jun 2020 //
PRNEWSWIRE
Takeda China announces ADCETRIS® is approved for treatment
14 May 2020 //
PRESS RELEASE
ADC upsizes IPO offering in search of a $175M-plus haul
14 May 2020 //
ENDPTS
EMA committee recommends approval of Takeda’s Adcetris in combo
01 Apr 2020 //
PHARMABIZ
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin)
31 Mar 2020 //
BUSINESSWIRE
Keytruda improves PFS in classical Hodgkin lymphoma
03 Mar 2020 //
PHARMATIMES
Merck`s Keytruda beats SeaGen’s Adcetris in cHL study
02 Mar 2020 //
FIERCE PHARMA
Merck’s KEYTRUDA® Significantly Improved ProgFree Survival Brentuximab Vedotin
02 Mar 2020 //
BUSINESSWIRE
Adcetris slows, but Padcev shines at Seattle Genetics
07 Feb 2020 //
FIERCE PHARMA
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS®
09 Dec 2019 //
BUSINESSWIRE
Seattle Genetics Announces Health Canada Approval of ADCETRIS®
25 Nov 2019 //
BUSINESS WIRE
Seattle Genetics makes case it can be more than Adcetris
30 Sep 2019 //
BIOPHARMADIVE
Enforcement Report - Week of August 21, 2019
21 Aug 2019 //
FDA
Seattle Genetics Announces Pricing of PO of Common Stock at $70.00 per share
23 Jul 2019 //
BIOSPACE
Takeda using “every possible channel” to deliver on Adcetris potential
22 Jul 2019 //
THE PHARMALETTER
Seattle Genetics investors breathe a sigh of relief as Adcetris posts 30% growth
17 Jul 2019 //
FIERCE PHARMA
Takeda to Showcase Growing Pipeline & Diversified Portfolio of Oncology Products
16 May 2019 //
BUSINESSWIRE
Seattle Genetics Announces Progress in Expanding ADCETRIS®
06 May 2019 //
BUSINESSWIRE
European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD
11 Feb 2019 //
BUSINESSWIRE
Seattle Genetics gets $30 mn for EC Approval of ADCETRIS (Brentuximab Vedotin)
11 Feb 2019 //
BUSINESSWIRE
Researchers spotlight good response rates for ADC in Seattle Genetics’ pipeline
08 Feb 2019 //
ENDPTS
Meeting highlights from the CHMP 10-13 December 2018
14 Dec 2018 //
FDA approves first-line treatment for peripheral T-cell lymphoma
16 Nov 2018 //
FDA
